cfDNA for Liquid Biopsy for Patients With Glioblastoma

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Bagley

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

2024 Neuro-Oncology Update: Brain Tumors

Scripps Health

T. McGranahan

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

Overview and Updates in Brain Tumors

Henry Friedman

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Vanderbilt University Medical Center (VUMC)

D. Johnson

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar